Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus AZOLID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus AZOLID.
ANAPROX DS vs AZOLID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically interfering with peptidoglycan cross-linking.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
2 g intravenously every 6-8 hours; maximum 8 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
Clinical Note
moderateFurazolidone + Torasemide
"Furazolidone may increase the hypotensive activities of Torasemide."
Clinical Note
moderateFurazolidone + Travoprost
"Furazolidone may increase the hypotensive activities of Travoprost."
Clinical Note
moderateFurazolidone + Unoprostone
"Furazolidone may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateFurazolidone + Hydrochlorothiazide
"Furazolidone may increase the hypotensive activities of Hydrochlorothiazide."
Terminal half-life 1.5-2 hours in normal renal function; prolonged to 4-8 hours in severe renal impairment (CrCl <30 mL/min)
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Renal (80-90% unchanged), biliary/fecal (10-20%)
Category C
Category C
NSAID
NSAID